Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of "Buy" from Analysts

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) has received an average rating of "Buy" from the six research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $17.50.

Several brokerages have commented on PHAT. Craig Hallum upped their price target on Phathom Pharmaceuticals from $12.00 to $17.00 and gave the stock a "buy" rating in a research note on Monday, June 9th. Guggenheim dropped their price target on Phathom Pharmaceuticals from $18.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Needham & Company LLC restated a "buy" rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday, June 6th. HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Phathom Pharmaceuticals in a research note on Monday, June 9th. Finally, The Goldman Sachs Group dropped their price target on Phathom Pharmaceuticals from $10.00 to $5.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd.

Institutional Investors Weigh In On Phathom Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Phathom Pharmaceuticals by 3.1% in the fourth quarter. Vanguard Group Inc. now owns 2,779,561 shares of the company's stock valued at $22,570,000 after buying an additional 83,238 shares in the last quarter. Wasatch Advisors LP grew its stake in shares of Phathom Pharmaceuticals by 531.3% in the fourth quarter. Wasatch Advisors LP now owns 1,558,928 shares of the company's stock valued at $12,658,000 after buying an additional 1,311,986 shares in the last quarter. 683 Capital Management LLC grew its stake in shares of Phathom Pharmaceuticals by 41.0% in the first quarter. 683 Capital Management LLC now owns 1,445,000 shares of the company's stock valued at $9,060,000 after buying an additional 420,000 shares in the last quarter. Catalys Pacific LLC grew its stake in shares of Phathom Pharmaceuticals by 4.0% in the fourth quarter. Catalys Pacific LLC now owns 1,167,114 shares of the company's stock valued at $9,477,000 after buying an additional 44,542 shares in the last quarter. Finally, Propel Bio Management LLC grew its stake in shares of Phathom Pharmaceuticals by 14.6% in the first quarter. Propel Bio Management LLC now owns 1,134,927 shares of the company's stock valued at $7,116,000 after buying an additional 145,000 shares in the last quarter. Institutional investors and hedge funds own 99.01% of the company's stock.

Phathom Pharmaceuticals Stock Performance

Phathom Pharmaceuticals stock traded down $0.21 during trading on Friday, hitting $8.33. The company's stock had a trading volume of 1,678,941 shares, compared to its average volume of 1,546,992. The stock has a market capitalization of $581.55 million, a price-to-earnings ratio of -1.59 and a beta of 0.45. The stock's fifty day moving average is $7.04 and its 200 day moving average is $6.09. Phathom Pharmaceuticals has a 1-year low of $2.21 and a 1-year high of $19.71.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.